Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AATec Medical & Northway Biotech Develop ATL-105 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AATec Medical & Northway Biotech Develop ATL-105

The two companies will develop and scale production for a novel recombinant version of alpha-1 antitrypsin targeting lung diseases.

By: Rachel Klemovitch

Assistant Editor

AATec Medical GmbH (AATec), a biotech company developing a multi-product platform to treat respiratory diseases, and Northway Biotech (NBT), a global CDMO, partnered for manufacturing process development and analytical development of AATec’s lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).

Per the agreement, NBT will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system.

ATL-105 was developed to treat NCFB, a chronic inflammatory respiratory condition. This disease is marked by dilated bronchi, persistent inflammation, frequent airway infections, and impaired mucus clearance. 

In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, including COPD, ARDS, and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties.

Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, said, ”ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and anti-infective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics